319 related articles for article (PubMed ID: 22325689)
1. Comparison of antibiotic susceptibility patterns in Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) with invasive Pseudomonas aeruginosa from non-CF patients.
Rao P; McCaughan J; McCalmont M; Goldsmith CE; Hall V; Millar BC; McCann MA; Downey DG; Rendall JC; Elborn JS; Moore JE
J Cyst Fibros; 2012 Jul; 11(4):349-52. PubMed ID: 22325689
[No Abstract] [Full Text] [Related]
2. Direct comparison of in vitro susceptibility of wildtype clinical Pseudomonas aeruginosa isolated from adult patients with cystic fibrosis (CF) to TOBI and BRAMITOB (tobramycin inhalation solutions).
Moore JE; Maeda Y; Goldsmith CE; Rendall JC; Elborn JS
J Cyst Fibros; 2010 May; 9(3):237-8. PubMed ID: 20378421
[No Abstract] [Full Text] [Related]
3. Consequences of combining cystic fibrosis- and non-cystic fibrosis-derived Pseudomonas aeruginosa antibiotic susceptibility results in hospital antibiograms.
Bosso JA; Mauldin PD; Steed LL
Ann Pharmacother; 2006 Nov; 40(11):1946-9. PubMed ID: 17018687
[TBL] [Abstract][Full Text] [Related]
4. Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population.
Bradbury R; Champion A; Reid DW
Respirology; 2008 Nov; 13(6):886-92. PubMed ID: 18811887
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.
Manno G; Cruciani M; Romano L; Scapolan S; Mentasti M; Lorini R; Minicucci L
Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511
[TBL] [Abstract][Full Text] [Related]
6. Genotyping of Pseudomonas aeruginosa in cystic fibrosis suggests need for segregation.
Edenborough FP; Stone HR; Kelly SJ; Zadik P; Doherty CJ; Govan JR
J Cyst Fibros; 2004 Mar; 3(1):37-44. PubMed ID: 15463885
[TBL] [Abstract][Full Text] [Related]
7. Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis.
Ferroni A; Guillemot D; Moumile K; Bernede C; Le Bourgeois M; Waernessyckle S; Descamps P; Sermet-Gaudelus I; Lenoir G; Berche P; Taddei F
Pediatr Pulmonol; 2009 Aug; 44(8):820-5. PubMed ID: 19598278
[TBL] [Abstract][Full Text] [Related]
8. Variable antibiotic susceptibility in populations of Pseudomonas aeruginosa infecting patients with bronchiectasis.
Gillham MI; Sundaram S; Laughton CR; Haworth CS; Bilton D; Foweraker JE
J Antimicrob Chemother; 2009 Apr; 63(4):728-32. PubMed ID: 19193658
[TBL] [Abstract][Full Text] [Related]
9. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
[TBL] [Abstract][Full Text] [Related]
10. Stationary biofilm growth normalizes mutation frequencies and mutant prevention concentrations in Pseudomonas aeruginosa from cystic fibrosis patients.
García-Castillo M; del Campo R; Baquero F; Morosini MI; Turrientes MC; Zamora J; Cantón R
Clin Microbiol Infect; 2011 May; 17(5):704-11. PubMed ID: 20673272
[TBL] [Abstract][Full Text] [Related]
11. Fosfomycin for Pseudomonas-related exacerbations of cystic fibrosis.
Faruqi S; McCreanor J; Moon T; Meigh R; Morice AH
Int J Antimicrob Agents; 2008 Nov; 32(5):461-3. PubMed ID: 18703318
[No Abstract] [Full Text] [Related]
12. Post-antibiotic effect of colistin, alone and in combination with amikacin, on Pseudomonas aeruginosa strains isolated from cystic fibrosis patients.
Bozkurt-Güzel C; Gerçeker AA
J Antibiot (Tokyo); 2012 Feb; 65(2):83-6. PubMed ID: 22126897
[No Abstract] [Full Text] [Related]
13. Pseudomonas aeruginosa and the airways disease of cystic fibrosis.
Hata JS; Fick RB
Clin Chest Med; 1988 Dec; 9(4):679-89. PubMed ID: 3148384
[TBL] [Abstract][Full Text] [Related]
14. Genotype and antibiotic susceptibility patterns of Pseudomonas aeruginosa and Stenotrophomonas maltophilia isolated from cystic fibrosis patients.
Nazik H; Ongen B; Erturan Z; Salcioğlu M
Jpn J Infect Dis; 2007 May; 60(2-3):82-6. PubMed ID: 17515637
[TBL] [Abstract][Full Text] [Related]
15. Early Pseudomonas aeruginosa infection in individuals with cystic fibrosis: is susceptibility testing justified?
Macdonald D; Cuthbertson L; Doherty C; Campana S; Ravenni N; Taccetti G; Govan JR
J Antimicrob Chemother; 2010 Nov; 65(11):2373-5. PubMed ID: 20837573
[TBL] [Abstract][Full Text] [Related]
16. Chromosomal mechanisms of aminoglycoside resistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients.
Islam S; Oh H; Jalal S; Karpati F; Ciofu O; Høiby N; Wretlind B
Clin Microbiol Infect; 2009 Jan; 15(1):60-6. PubMed ID: 19154484
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis.
Etherington C; Hall M; Conway S; Peckham D; Denton M
J Antimicrob Chemother; 2008 Feb; 61(2):425-7. PubMed ID: 18156280
[TBL] [Abstract][Full Text] [Related]
18. Characterization of clonal strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients in Ontario, Canada.
Beaudoin T; Aaron SD; Giesbrecht-Lewis T; Vandemheen K; Mah TF
Can J Microbiol; 2010 Jul; 56(7):548-57. PubMed ID: 20651854
[TBL] [Abstract][Full Text] [Related]
19. Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.
Millar BC; McCaughan J; Rendall JC; Downey DG; Moore JE
J Clin Pharm Ther; 2018 Feb; 43(1):92-100. PubMed ID: 29293275
[TBL] [Abstract][Full Text] [Related]
20. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa.
Herrmann G; Yang L; Wu H; Song Z; Wang H; Høiby N; Ulrich M; Molin S; Riethmüller J; Döring G
J Infect Dis; 2010 Nov; 202(10):1585-92. PubMed ID: 20942647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
